IOncology

The Northern Breast Cancer Salon was recently held successfully in Qingdao. The meeting focused on the latest advances and clinical hot topics in breast cancer, bringing together numerous experts and scholars for in-depth academic exchange. During the meeting, Professor Wenyan Chen of Nanchang People's Hospital and Professor Ning Xie of Hunan Cancer Hospital respectively shared their perspectives on “Treatment options for HER2-positive metastatic breast cancer after failure of H-based therapy — T-DXd, SHR-A1811, and others.” Following the meeting, Oncology Frontier invited the two professors to further review and elaborate on their respective perspectives, with the aim of providing clinicians with clearer insights and practical guidance on treatment selection after failure of H-based therapy.

Over the past two decades, the treatment of HER2-positive breast cancer has undergone a dramatic transformation, evolving from targeted therapy to the era of antibody-drug conjugates (ADCs), with substantial improvements in patient survival and prognosis. Recently, the Northern Breast Cancer Salon was successfully held in Qingdao. During the meeting, Oncology Frontier interviewed Professor Guohong Song of Peking University Cancer Hospital, who provided an in-depth overview of milestone developments in the treatment of HER2-positive breast cancer, individualized treatment strategies involving treatment “escalation” and “de-escalation” in early breast cancer, and the changes and future prospects brought about by ADC therapies.

Breast cancer is the most commonly diagnosed malignancy among women worldwide. Looking back over the past century, its diagnosis and treatment have evolved from viewing breast cancer primarily as a locoregional disease treated mainly with surgery, to recognizing its systemic nature and developing systemic therapies, and ultimately to the clinical adoption of molecular subtype-based treatment. Each transformation has brought significant improvements in patient survival and prognosis. Today, with continued advances in genetic testing technologies, breast cancer treatment is evolving further from molecular subtype-based approaches toward precision treatment guided by genetic alterations. Recently, the Northern Breast Cancer Salon was successfully held in Qingdao. Professor Yongmei Yin of Jiangsu Provincial People's Hospital delivered a presentation entitled “Seeing the Subtle to Foresee the Far — The Evolution of Precision Diagnosis and Treatment in Breast Cancer from Molecular Subtyping to Gene-Guided Therapy,” systematically reviewing the evolution and breakthroughs in breast cancer treatment strategies and providing an in-depth interpretation of the emerging landscape of precision therapy, from molecular subtyping to gene-driven treatment. This article summarizes the key points of her presentation, with the aim of providing reference and inspiration for clinical practice.

Recently, the Northern Breast Cancer Salon was successfully held in Qingdao, bringing together leading experts and scholars to discuss the latest advances and clinical hot topics in breast cancer. During the meeting, Professor Jin Yang of the First Affiliated Hospital of Xi'an Jiaotong University delivered a systematic and insightful presentation on controversial issues surrounding immunotherapy for advanced breast cancer. Oncology Frontier interviewed Professor Yang during the meeting to discuss current controversies in immunotherapy, key topics under consideration for the new edition of the Chinese Expert Consensus on the Clinical Application of Immunotherapy for Breast Cancer, and the challenges of translating these recommendations into clinical practice.

: Breast cancer is one of the most active fields in oncology research and translational medicine. From HER2-targeted therapy to individualized treatment guided by molecular subtyping, numerous basic research discoveries have profoundly transformed clinical practice. During the 10th Yunling Breast Cancer Conference, held in Kunming on August 21–22, 2026, Professor Cexi Chen of Yunnan Cancer Hospital spoke with Oncology Frontier about the directions most likely to drive breakthroughs in basic breast cancer research in China, the key barriers to translating basic discoveries into clinical applications, and the development pathways for young researchers. He highlighted the translational potential of antibody-drug conjugates (ADCs), proteolysis-targeting chimeras (PROTACs), and organoids, emphasizing that breast cancer basic research should always be grounded in unmet clinical needs and should use original technologies with practical value to drive innovation in diagnostic and treatment paradigms.

Since its establishment in 2016, the Yunling Breast Cancer Conference has been successfully held for ten consecutive editions. It has evolved from a learning and exchange platform initially serving breast cancer professionals in Yunnan Province into a major academic meeting with influence across Southwest China and nationally. The 10th Yunling Breast Cancer Conference was held in Kunming from August 21–23, 2026. During the conference, Professor Jianyun Nie, Vice President of Yunnan Cancer Hospital, reviewed the ten-year development of the conference and shared his perspectives on standardized breast cancer diagnosis and treatment in the region, capacity building in primary healthcare institutions, and the precision-driven evolution of breast surgery.

The 10th Yunling Breast Cancer Conference was held in Kunming from August 21–22, 2026. After a decade of development, the Yunling Breast Cancer Conference has evolved from a regional academic exchange platform into a widely influential breast cancer academic brand. With the theme “Inheritance, Innovation, and Vision,” this year's conference not only brought together leading experts in breast cancer from across China, but also actively incorporated cutting-edge developments from interdisciplinary fields including molecular medicine, artificial intelligence, and materials science, showcasing new advances in breast cancer basic research and clinical practice.

HR+/HER2− breast cancer is the most common molecular subtype of breast cancer, and the combination of CDK4/6 inhibitors and endocrine therapy has become an important standard first-line treatment for patients with advanced disease. With the increasing availability of PI3K/AKT/mTOR (PAM) pathway inhibitors, novel endocrine therapies, and antibody-drug conjugates (ADCs), the treatment of advanced HR+/HER2− breast cancer is gradually evolving from a relatively fixed sequential treatment model toward precision stratification based on molecular characteristics.